Table 2.
Results of the subgroup analysis
| Subgroup | HR | LL | UL | N | I2 | P | Heterogeneity between groups: p value |
|---|---|---|---|---|---|---|---|
| Total | 1.25 | 1.06 | 1.47 | 15 | 89.7% | 0.000 | |
| Influence | 0.000 | ||||||
| Oncogenic | 1.60 | 1.35 | 1.60 | 9 | 92.1% | 0.000 | |
| Tumor suppressive | 0.42 | 0.30 | 0.57 | 6 | 0.0% | 0.501 | |
| Prognosis | 0.778 | ||||||
| OS | 1.20 | 1.02 | 1.42 | 8 | 89.8% | 0.000 | |
| PFS | 1.09 | 0.53 | 2.22 | 7 | 90.5% | 0.000 | |
| Resources | 0.000 | ||||||
| serum | 2.15 | 0.57 | 8.17 | 3 | 95.6% | 0.000 | |
| plasma | 1.98 | 1.41 | 2.80 | 3 | 0.0% | 0.551 | |
| tumor | 0.97 | 0.84 | 1.12 | 9 | 84.2% | 0.000 | |
| miRNA Panel | 0.215 | ||||||
| 1 | 1.25 | 1.06 | 1.48 | 11 | 90.9% | 0.000 | |
| 2 | 0.64 | 0.14 | 3.00 | 3 | 90.8% | 0.000 | |
| 3 | 2.10 | 1.10 | 4.01 | 1 | 0.0% | . | |
| Follow-up time | 0.056 | ||||||
| <50 months | 1.84 | 0.97 | 3.46 | 8 | 87.8% | 0.000 | |
| >50 months | 0.97 | 0.84 | 1.1290.8$ | 7 | 86.1% | 0.000 |
LL lower limit, UL upper limit